Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

A report released Thursday said highly processed foods, exposure to chemicals and excessive use of prescription drugs are ...

They're brightly colored, packed in enticing boxes and often marketed as healthy -- but many cereals today are actually less ...

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Introduced in January this year, the new PPRS pricing scheme represents a major change in how the UK pays for branded medicines. The Pharmaceutical Price Regulation Scheme (PPRS) has been around ...